This finding aligns with the guidelines from the Pan-Asian and European Society for Medical Oncology (ESMO) [28,29], which recommend considering anti-EGFR therapy for potentially resectable right-sided colorectal cancer metastases in patients with wild-type RAS/BRAF, although our recommendation is based on pathological response. The gene discussed is EGFR; the disease is colorectal cancer.